Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Re-treatment of relapsed indolent B-cell lymphoma with rituximab.
Igarashi T, Ohtsu T, Fujii H, Sasaki Y, Morishima Y, Ogura M, Kagami Y, Kinoshita T, Kasai M, Kiyama Y, Kobayashi Y, Tobinai K; IDEC-C2B8 Study Group. Igarashi T, et al. Among authors: ohtsu t. Int J Hematol. 2001 Feb;73(2):213-21. doi: 10.1007/BF02981940. Int J Hematol. 2001. PMID: 11372734 Clinical Trial.
Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508.
Kagami Y, Itoh K, Tobinai K, Fukuda H, Mukai K, Chou T, Mikuni C, Kinoshita T, Fukushima N, Kiyama Y, Suzuki T, Sasaki T, Watanabe Y, Tsukasaki K, Hotta T, Shimoyama M, Ogura M; Lymphoma Study Group of the Japan Clinical Oncology Group. Kagami Y, et al. Int J Hematol. 2012 Jul;96(1):74-83. doi: 10.1007/s12185-012-1101-2. Epub 2012 Jun 3. Int J Hematol. 2012. PMID: 22661011 Clinical Trial.
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M. Ogura M, et al. Among authors: ohtsu t. Int J Hematol. 2010 Dec;92(5):713-24. doi: 10.1007/s12185-010-0712-8. Epub 2010 Nov 16. Int J Hematol. 2010. PMID: 21076995 Clinical Trial.
Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.
Izutsu K, Minami Y, Fukuhara N, Terui Y, Jo T, Yamamoto G, Ishikawa T, Kobayashi T, Kiguchi T, Nagai H, Ohtsu T, Kalambakas S, Fustier P, Midorikawa S, Tobinai K. Izutsu K, et al. Among authors: ohtsu t. Int J Hematol. 2020 Mar;111(3):409-416. doi: 10.1007/s12185-019-02802-y. Epub 2019 Dec 19. Int J Hematol. 2020. PMID: 31858429 Clinical Trial.
169 results